| 000 | 01799 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515161613.0 | ||
| 264 | 0 | _c20090616 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.24221 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKyle, Robert A | |
| 245 | 0 | 0 |
_aThe treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. _h[electronic resource] |
| 260 |
_bCancer _cMay 2009 |
||
| 300 |
_a2155-64 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCarmustine _xadverse effects |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon Type I _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aPrednisone _xadverse effects |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aVincristine _xadverse effects |
| 700 | 1 | _aJacobus, Susanna | |
| 700 | 1 | _aFriedenberg, William R | |
| 700 | 1 | _aSlabber, Coenraad Frederik | |
| 700 | 1 | _aRajkumar, S Vincent | |
| 700 | 1 | _aGreipp, Philip R | |
| 773 | 0 |
_tCancer _gvol. 115 _gno. 10 _gp. 2155-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.24221 _zAvailable from publisher's website |
| 999 |
_c18689436 _d18689436 |
||